Galectin Therapeutics Stock Alpha and Beta Analysis

GALT Stock  USD 2.78  0.06  2.21%   
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Galectin Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Galectin Therapeutics over a specified time horizon. Remember, high Galectin Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Galectin Therapeutics' market risk premium analysis include:
Beta
1.67
Alpha
0.13
Risk
3.41
Sharpe Ratio
0.0773
Expected Return
0.26
Please note that although Galectin Therapeutics alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., Dow Jones Industrial index.) So in this particular case, Galectin Therapeutics did 0.13  better than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of Galectin Therapeutics stock's relative risk over its benchmark. Galectin Therapeutics has a beta of 1.67  . As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Galectin Therapeutics will likely underperform. Enterprise Value is likely to gain to about 104.5 M in 2024, despite the fact that Book Value Per Share is likely to grow to (0.95).

Enterprise Value

104.48 Million

Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
  
Check out Galectin Therapeutics Backtesting, Galectin Therapeutics Valuation, Galectin Therapeutics Correlation, Galectin Therapeutics Hype Analysis, Galectin Therapeutics Volatility, Galectin Therapeutics History and analyze Galectin Therapeutics Performance.
For more information on how to buy Galectin Stock please use our How to Invest in Galectin Therapeutics guide.

Galectin Therapeutics Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Galectin Therapeutics market risk premium is the additional return an investor will receive from holding Galectin Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Galectin Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Galectin Therapeutics' performance over market.
α0.13   β1.67

Galectin Therapeutics expected buy-and-hold returns

Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Galectin Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Galectin Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.

Galectin Therapeutics Market Price Analysis

Market price analysis indicators help investors to evaluate how Galectin Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Galectin Therapeutics shares will generate the highest return on investment. By understating and applying Galectin Therapeutics stock market price indicators, traders can identify Galectin Therapeutics position entry and exit signals to maximize returns.

Galectin Therapeutics Return and Market Media

The median price of Galectin Therapeutics for the period between Mon, Aug 26, 2024 and Sun, Nov 24, 2024 is 2.69 with a coefficient of variation of 5.41. The daily time series for the period is distributed with a sample standard deviation of 0.14, arithmetic mean of 2.67, and mean deviation of 0.11. The Stock received substential amount of media coverage during this period.
 Price Growth (%)  
       Timeline  
1
Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
09/03/2024
2
Galectin Therapeutics Downgraded by StockNews.com - MarketBeat
09/27/2024
3
Acquisition by Freeman Kevin D of 5000 shares of Galectin Therapeutics at 2.7 subject to Rule 16b-3
10/16/2024
4
Acquisition by Freeman Kevin D of 1300 shares of Galectin Therapeutics at 2.64 subject to Rule 16b-3
10/17/2024
5
Insider Trading
10/25/2024
6
Galectin Therapeutics GAAP EPS of -0.18
11/14/2024
7
Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases 2024 Liver Meeting
11/18/2024
8
StockNews.com Upgrades Galectin Therapeutics to Hold - MarketBeat
11/20/2024

About Galectin Therapeutics Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Galectin or other stocks. Alpha measures the amount that position in Galectin Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.

Galectin Therapeutics Upcoming Company Events

As portrayed in its financial statements, the presentation of Galectin Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Galectin Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Galectin Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Galectin Therapeutics. Please utilize our Beneish M Score to check the likelihood of Galectin Therapeutics' management manipulating its earnings.
4th of April 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Build Portfolio with Galectin Therapeutics

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Additional Tools for Galectin Stock Analysis

When running Galectin Therapeutics' price analysis, check to measure Galectin Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galectin Therapeutics is operating at the current time. Most of Galectin Therapeutics' value examination focuses on studying past and present price action to predict the probability of Galectin Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galectin Therapeutics' price. Additionally, you may evaluate how the addition of Galectin Therapeutics to your portfolios can decrease your overall portfolio volatility.